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 22 
Abstract: Ellipticine is a DNA-damaging agent acting as a prodrug whose 23 
pharmacological efficiencies and genotoxic side effects are dictated by activation with 24 
cytochrome P450 (CYP). Over the last decade we have gained extensive experience in 25 
using pure enzymes and various animal models that helped to identify CYPs metabolizing 26 
ellipticine. In this review we focus on comparison between the in-vitro and in-vivo studies 27 
and show a necessity of both approaches to obtain valid information on CYP enzymes 28 
contributing to ellipticine metabolism. The discrepancies were found between the CYP 29 
enzymes activating ellipticine to 13-hydroxy- and 12-hydroxyellipticine generating 30 
covalent DNA adducts and those detoxifying this drug to 9-hydroxy- and 7-31 
hydroellipticine in vitro and in vivo. In vivo, formation of ellipticine-DNA adducts is 32 
dependent not only on expression levels of CYP3A, catalyzing ellipticine activation in 33 
vitro, but also on those of CYP1A that oxidize ellipticine in vitro mainly to the 34 
detoxification products. The finding showing that cytochrome b5 modulates patterns of 35 
ellipticine metabolites formed by CYP1A1/2 and 3A explained this paradox. Cytochrome 36 
b5 alters the ratio of ellipticine metabolites generated by CYP1A1/2 and 3A4. Whereas 37 
formation of detoxification ellipticine metabolites by CYP1A and 3A are either decreased 38 
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or not changed with cytochrome b5, formation of activation metabolites and ellipticine-39 
DNA adducts increased considerably. We demonstrate that (i) ellipticine pharmacological 40 
effects mediated by covalent ellipticine-derived DNA adducts are dictated by expression 41 
levels of CYP1A, 3A and cytochrome b5, and its own potency to induce these enzymes in 42 
tumor tissues, (ii) the animal models, where levels of CYPs are regulated both by their 43 
knockout and/or induction are appropriate to identify CYPs metabolizing ellipticine in 44 
vivo, and (iii) extrapolation from in-vitro data to situation in vivo is not always possible, 45 
confirming the need for these animal models. 46 
Keywords: Anticancer drug ellipticine; Cytochrome P450 mediated DNA-damage; 47 
Covalent DNA adducts; Enzymes metabolizing ellipticine in vitro and in vivo 48 
 49 
1. Introduction 50 
A plant alkaloid ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole, Figure 1) found in several 51 
Apocynaceae plants and its derivatives are efficient anticancer compounds that function through 52 
multiple mechanisms participating in cell cycle arrest and initiation of apoptosis (for a summary see) [1-53 
6]. Ellipticine was found (i) to arrest cell cycle progression due to modulation of levels of cyclinB1 and 54 
Cdc2, and phosphorylation of Cdc2 in human mammary adenocarcinoma MCF-7 cells, (ii) to initiate 55 
apoptosis due to formation of toxic free radicals, stimulation of the Fas/Fas ligand system and 56 
modulation of proteins of Bcl-2 family in several tumor cell lines, and (iii) to induce the mitochondria-57 
dependent apoptotic processes (for a summary see) [3,4].  58 
Several studies also demonstrated that p53 tumor suppressor protein is involved in ellipticine-59 
mediated induction of cell cycle arrest and apoptosis [7-13]. Ellipticine inhibits p53 protein 60 
phosphorylation by a selective inhibition of CDK2 kinase in Lewis lung carcinoma and human colon 61 
cancer cell line SW480 [7], and this effect on p53 correlated with cytotoxic activity of ellipticine [7]. 62 
Treatment of Saos 2 cells transfected with mutant p53 with ellipticine restored the transactivation 63 
function of p53, resulting in the induction of p53-responsive p21Waf1 and MDM2 genes at protein levels 64 
and activation of a p53-responsive luciferase reporter [12]. The results found in the study of Sugikawa 65 
and coworkers [12] indicate that ellipticine induces a shift of mutant p53 conformation towards wild-66 
type and this activity is not caused by its function as an inhibitor of topoisomerase II, which is one of the 67 
DNA-damaging effects of ellipticine (for a summary see [1-6]). More importantly, ellipticine can even 68 
activate mutant p53 and induces p21Waf1 and MDM2 gene expression in vivo, in nude mouse tumor 69 
xenografts [13].  70 
Ellipticine also modulates p53 nuclear localization in HCT116 colon cancer cells. It elevated the 71 
nuclear localization of endogenous p53 and exogenous mutant p53 with a resultant increase in the 72 
transactivation of the p21 promoter. Nuclear localization of p53 is frequently the consequence of a 73 
genotoxic stress by compounds inducing DNA damage (i.e. inhibitors of topoisomerase II)[14].  The 74 
ellipticine-mediated abundance of nuclear p53 was not associated with an increase in DNA double 75 
strand breaks. Therefore, this effect of ellipticine seems not to be dependent on the mechanism mediated 76 
by topoisomerase II inhibition, but on another genotoxic stress [15]. Ellipticine also activates the p53 77 
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pathway in glioblastoma cells; its impact on these cancer cells depends on the p53 status [11].  In a 78 
U87MG glioblastoma cell line expressing wild-type p53, ellipticine provoked an early G0/G1 cell cycle 79 
arrest, whereas in a U373 cell line expressing a p53 mutant it induced arrest in S and G2/M phases of the 80 
cell cycle [11].  81 
Figure 1. Ellipticine.  82 
 83 
 84 
 85 
 86 
 87 
All studies investigating the mechanism of ellipticine antitumor action indicate complex pathways 88 
leading to cancer cell death by this drug. Chemotherapy-induced cell cycle arrest and induction of 89 
apoptosis were shown to frequently result from DNA damage caused by exposure to a variety of 90 
chemotherapeutics including ellipticine. In addition, a genotoxic stress resulting from several DNA-91 
damaging agents including ellipticine increases levels of nuclear p53 [14,15], the tumor suppressor 92 
protein known to be involved in ellipticine-mediated induction of cell cycle arrest and apoptosis [7-13]. 93 
These findings suggest that a role of ellipticine as a DNA-damaging agent is crucial for its cytotoxic 94 
effects.  95 
2. DNA-damaging mechanisms of ellipticine cytotoxicity to cancer cells 96 
Of the DNA-damaging mechanisms of ellipticine’s biological effects, intercalation into DNA [5,16-97 
19] and inhibition of DNA topoisomerase II activity [5,20,21] were considered to be most important. 98 
However, we showed that this antitumor agent causes also damage to the structural integrity of DNA 99 
through covalent binding, by forming covalent DNA adducts after its enzymatic activation with 100 
cytochromes P450 (CYP) and peroxidases [1-4,22-31]. Moreover, cytotoxicity of ellipticine to several 101 
cancer cells sensitive to this drug such as HL-60 promyelocytic leukemia and T-cell leukemia CCRF-102 
CEM cells, glioblastoma U87MG cells, neuroblastoma UKF-NB-3 and UKF-NB-4 cell lines, thyroid 103 
cancer BHT-101, B-CPAP and 8505-C cells and breast adenocarcinoma MCF-7 cells corresponds to 104 
levels of ellipticine-derived DNA adducts generated after its enzymatic activation in most these cells 105 
[32]. This indicates that covalent modification of DNA by the reactive species generated with enzyme-106 
mediated bioactivation of ellipticine is one of the most important mechanisms responsible for ellipticine 107 
cytotoxicity in these cancer cells. Based on these results, we suggest that ellipticine acts as a prodrug, 108 
which is metabolically activated to reactive species forming covalent DNA adducts causing genotoxic 109 
stress. Therefore, information on which enzymes are involved in the metabolism of ellipticine is critical 110 
for identification of ellipticine pharmacological effects. Several in vitro and in vivo approaches have 111 
been developed to study a role of specific CYP and peroxidase enzymes in ellipticine metabolism.   112 
Over the past 10 years we have gained extensive experience in using the pure enzymes and the 113 
various animal models to study the ellipticine metabolism. During these studies, ellipticine was found to 114 
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be oxidized by CYP and peroxidase enzymes to both electrophilic species forming covalent DNA 115 
adducts detected by 32P-postalbeling (Figure 2) and to detoxification metabolites [1-4,23-31,33-42]. 116 
Moreover, we characterized reactions leading to their formation. 117 
Figure 2. Autoradiographs of thin layer chromatography (TLC) maps of 32P-labeled digests of 118 
calf thymus DNA reacted with ellipticine activated by hepatic microsomes from wild-type 119 
(WT) mice (A), with those of Hepatic Cytochrome P450 Reductase Null (HRN) mice treated 120 
with benzo[a]pyrene (BaP) (B), from calf thymus DNA reacted with 13-hydroxyellipticine (C) 121 
[22] and 12-hydroxyellipticine (D) [23] of DNA from livers of WT (E) and HRN (F) mice 122 
treated i.p. with 10 mg ellipticine/kg body weight [39] and of DNA from liver DNA of Wistar 123 
rats treated i.p. with 40 mg ellipticine per kilogram body weight (G) [24,28]. Analyses were 124 
performed by the nuclease P1 version of the 32P-postlabeling assay. Adduct spots 1-7  and A 125 
correspond to the ellipticine-derived DNA adducts. Besides adduct 2 formed by 12-126 
hydroxyellipticine, another strong adduct (spot X in panel D), which was not found in any 127 
other activation systems or in vivo was generated. 128 
 129 
 130 
In this review we focus on comparison between the data found in the in-vitro and in-vivo studies 131 
investigating the ellipticine metabolism and show a necessity of both approaches to obtain valid 132 
information on CYP enzymes participating in this process.     133 
3. Metabolism of ellipticine by CYP, peroxidase and conjugation enzymes to activation and 134 
detoxification metabolites in vitro   135 
Utilizing numerous in vitro systems such as subcellular microsomal fractions and cells in culture 136 
expressing CYPs, isolated CYPs reconstituted with other components of the mixed-function-oxidase 137 
system [NADPH:CYP reductase (POR), cytochrome b5], and recombinant CYPs, the human, rat, rabbit, 138 
and mouse CYP enzymes were found to oxidize ellipticine. Up to five metabolites, 7-hydroxy-, 9-139 
hydroxy-, 12-hydroxy-, 13-hydroxyellipticine, and ellipticine N2-oxide (Figure 3), and at least two major 140 
ellipticine DNA-adducts were generated by these enzymatic systems [3,22,24-27,29-31,39,40].  141 
 142 
7-Hydroxy- and 9-hydroxyellipticine are considered to be the detoxification metabolites of 143 
ellipticine, because they are efficiently excreted by experimental animals [43,44]. 13-Hydroxy- and 12-144 
hydroxyellipticine are the active metabolites, because they are reactive compounds forming 145 
spontaneously ellipticine-13-ylium and ellipticine-12-ylium, which can generate two major 146 
deoxyguanosine adducts in DNA (see adduct spots 1 and 2 in Figure 2 and the proposed structures of 147 
these DNA adducts in Figure 3) [2-4,22,23,25-27,30,31,40]. In addition, ellipticine N2-oxide should be 148 
considered as another active ellipticine metabolite, because it rearranges to 12-hydroxyellipticine [22], 149 
by the Polonowski rearrangement [45] (Figure 3). All these results suggest that the enzymes activating 150 
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or detoxifying ellipticine are crucial for its pharmacological effects. Thus, the identification of enzymes 151 
necessary for ellipticine metabolism is of great importance.  152 
Using a panel of human recombinant CYPs, inhibitors of these enzymes in human hepatic 153 
microsomes and correlation analyses, the role of individual CYPs in the formation of ellipticine 154 
metabolites was identified [22,25,26,31]. Human recombinant CYP1A1 and 1A2, followed by CYP1B1, 155 
are the most efficient enzymes oxidizing ellipticine to 7-hydroxy- and 9-hydroxyellipticine (Figure 3) 156 
[22]. Thus, CYP1A are the most important enzymes detoxifying ellipticine. The activation metabolite, 157 
13-hydroxyellipticine, forming the ellipticine-DNA adduct 1 (Figure 2C), is generated predominantly by 158 
CYP3A4. Oxidation of ellipticine to another activation metabolite, 12-hydroxyellipticine, generating 159 
DNA adduct 2 (Figure 2D) is also catalyzed by CYP3A4, but more efficiently by CYP2C19. The N2-160 
oxide of ellipticine is generated beside CYP3A4 mainly by CYP2D6 [22,25,26,30]. These results 161 
demonstrate that CYP3A4 is the most effective enzyme that forms both ellipticine-DNA adducts 1 and 2 162 
(see adducts 1 and 2 in Figures 2 and 3),  while adduct 2 is also generated by CYP2C19 and 2D6. 163 
Moreover, orthologous CYP enzymes of rats and mice catalyze formation of these metabolites and DNA 164 
adducts [1-4,27,29]. This indicates that these animals might be suitable models mimicking the fate of 165 
ellipticine in human. 166 
Recently it was also found that levels of the DNA adduct formed by 13-hydroxyellipticine increased 167 
if this ellipticine metabolite was conjugated with sulfate or acetate by human sulfotransferases 1A1, 168 
1A2, 1A3 and 2A1, or N,O-acetyltransferases 1 and 2 (Figure 3) [25,46].  169 
Beside CYP enzymes, peroxidases are capable of oxidizing ellipticine. In vitro, human 170 
myeloperoxidase, bovine lactoperoxidase, ovine cyclooxygenase (COX)-1, human COX-2 and plant 171 
horseradish peroxidase are able to bio-activate ellipticine to form up to four DNA adducts [23]. 172 
Interestingly, even though mechanisms of oxidation of a variety of substrates including ellipticine by 173 
peroxidases and CYPs are different, two of the DNA adducts formed during oxidation of ellipticine by 174 
peroxidases are identical to those produced by 13-hydroxy- and 12-hydroxyellipticine generated by 175 
CYPs [23].  176 
Figure 3. Ellipticine metabolism by CYPs showing the identified metabolites and those 177 
proposed to form DNA adducts. The compounds shown in brackets were not detected under 178 
the experimental conditions and/or not yet structurally characterized. The CYP enzymes 179 
predominantly oxidizing ellipticine shown in the figure were identified in our previous studies 180 
[22,25,26,29,30]. Rea 1, 2 and 3 are reactions leading to ellipticine-13-ylium from 13-181 
hydroxyellipticine, 13-hydroxyellipticine sulfate and 13-hydroxyellipticine acetate, 182 
respectively. 183 
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 186 
Peroxidases oxidize ellipticine by a one-electron (radical) mechanism to two metabolites, the major 187 
metabolite is an ellipticine dimer between the N6 of one ellipticine molecule and C9 of another 188 
ellipticine molecule, and the second, minor one is ellipticine N2-oxide (Figure 4) [23]. The ellipticine 189 
dimer is not responsible for ellipticine-DNA adduct formation, but is formed when no other nucleophiles 190 
like DNA or proteins are present to intercept the reactive intermediates of ellipticine [23,47]. Hence, 191 
adduct formation is preferred to generation of dimer under physiological conditions. 192 
Figure 4. Metabolism of ellipticine by peroxidases showing the characterized metabolites and 193 
those proposed to form DNA adducts. The compounds shown in brackets were not detected 194 
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under the experimental conditions and are the electrophilic metabolites postulated as ultimate 195 
arylating species or the postulated N²-deoxyguanosine adducts (adapted from reference [23]).  196 
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 199 
Because DNA adduct 1 formed by 13-hydroxyellipticine is identical to the DNA adduct generated 200 
during ellipticine oxidation by peroxidases, 6,13-didehydroellipticine (the ellipticine methylene-imine) 201 
(Figure 4), was postulated to be the metabolite responsible for its generation. This compound should 202 
form ellipticine-13-ylium, the identical carbonium-cation as 13-hydroxyellipticine (Figure 4). Michael-203 
type addition of nucleophiles to the vinylogous imine of 6,13-didehydroellipticine then yields the same 204 
DNA adduct as the adduct generated by ellipticine-13-ylium [48]. The ellipticine-DNA adduct 2 205 
mediated by peroxidase is identical to that formed by 12-hydroxyelliptine. Because this metabolite is 206 
formed not only by ellipticine oxidation with CYPs, but also by the Polonowski rearrangement from 207 
ellipticne N2-oxide that is generated by peroxidases [23,45], the mechanism of its formation is easily 208 
explained. The ellipticine-12-ylium carbo-cation formed by dissociation of 12-hydroxyellipticine reacts 209 
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with deoxyguanosine in DNA to form the DNA adduct 2 (Figure 4) [23]. The other two DNA adducts, 210 
which are formed by the peroxidase-catalyzed activation of ellipticine (spots 6 and 7 in Figure 2) [23],  211 
are also observed during oxidation of ellipticine by microsomes isolated from livers of humans [22,49], 212 
rats [1,29,49], rabbits [1,29], and mice [39,50], and in several organs of mice (Figure 2E,F) and rats 213 
(Figure 2G) exposed to ellipticine [24,28,39]. In contrast, the other minor ellipticine-DNA adducts 214 
formed in vivo (see spots 3-5 in Figure 2) are not produced by ellipticine oxidation with peroxidase [23]. 215 
The structures of these minor ellipticine-DNA adducts (spots 3-7 in Figure 2) have not been identified as 216 
yet. 217 
4. Oxidation of ellipticine by CYP enzymes to activation and detoxification metabolites in vivo   218 
In order to extrapolate from the in-vitro data to the in-vivo situation, additional factors have to be 219 
considered such as route-of-administration, absorption, renal clearance, and tissue-specific expression of 220 
enzymes metabolizing ellipticine. To identify CYP enzymes responsible for activation of ellipticine in 221 
vivo, several animal models were used: (i) the wild-type (WT) and the Hepatic P450 Reductase Null 222 
(HRN) mice, (ii) the same mouse models, but in which expression of enzymes of the mixed-function 223 
oxidase system was induced by benzo[a]pyrene (BaP), and (iii) the Wistar rats. These studies 224 
demonstrated that utilizing knockout animals in combination with animal models, where expression of 225 
these enzymes was modulated by their inducers, is crucial for determining the fate of ellipticine and its 226 
DNA-damaging effects in vivo. In addition, the results found in experiments utilizing these models 227 
revealed a paradox: namely, the finding that CYP1A enzymes appear to be more important for activation 228 
of ellipticine in vivo, despite being involved in its metabolic detoxification in vitro. 229 
4.1. Utilization of WT and HRN mice to identify enzymes metabolizing ellipticine in vivo 230 
In HRN mice, mouse POR, the most important electron donor to mouse CYPs, is deleted 231 
specifically in hepatocytes. This model was developed by Henderson et al. [51] to evaluate the role of 232 
both hepatic POR and CYPs in xenobiotic metabolism. Deletion of this enzyme results not only in the 233 
loss of essentially all hepatic CYP function, but also in the lack of direct reduction of xenobiotics by 234 
POR, an additional property of this enzyme. This mouse model has been used successfully to 235 
investigate the role of hepatic versus extra-hepatic CYP-catalyzed metabolism and the disposition of 236 
several xenobiotics such as carcinogens and drugs including ellipticine [39,52-58].  237 
Using WT and HRN mouse lines, hepatic CYPs were demonstrated to be important in ellipticine-238 
derived DNA adduct formation also in vivo. In both mouse lines treated with ellipticine, up to seven 239 
ellipticine-specific DNA adducts were observed in liver, lung, kidney, spleen, colon and bladder (see 240 
Figure 2E,F for liver of WT and HRN mice). Adduct spots 1 and 2 derived from 13-hydroxy- and 12-241 
hydroxyellipticine, respectively, and deoxyguanosine residues in DNA (Figures 2 and 3) were the 242 
predominant adducts in all mouse tissues examined.  243 
The finding that ellipticine-DNA adducts are formed in all organs tested in used animal models 244 
suggest that ellipticine or its metabolites are distributed via the blood stream to different organs and 245 
that these tissues have the metabolic capacity to oxidatively activate ellipticine. As found by Chadwick 246 
and co-workers [43,44] ellipticine is very rapidly distributed from the blood, and its excretion is 247 
essentially complete by 24 hours in several species including mice, rats, dogs, and monkeys. The rate 248 
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of ellipticine elimination from blood was found to reflect the rate of metabolism of this drug [43]. The 249 
main organ responsible for its biotransformation was found to be the liver, forming predominantly 9-250 
hydroxyellipticine, which is excreted mainly in bile as its glucuronide or sulfate conjugate [43,44]. 251 
Other in-vivo pathways involving hydroxylation at as yet unknown positions have also been found 252 
[43,44]. As mentioned above, in in-vitro experiments, ellipticine is metabolized by CYP-mediated 253 
reactions by hepatic microsomes of a variety of organisms, including humans, rats, rabbits and mice 254 
[22,30,39,40,49,50] to several hydroxylated derivatives, with 9-hydroxy-, 12-hydroxy- and 13-255 
hydroxyellipticine being the major metabolites in most species. However, because 13-hydroxy- and 12-256 
hydroxyellipticine are reactive and have been found to form the two major ellipticine-DNA adducts 257 
[22,23,30,38], they will not be easily detectable in vivo. In addition, radioactively labelled ellipticine 258 
was found to be deposited in a number of organs with the highest levels in the liver, followed by 259 
kidney, lung, intestine and spleen, and was located primarily in the nuclear fraction [43]. One of the 260 
explanation for this may be the ellipticine-DNA binding that we found in these tissues [23,24,39]. 261 
The levels of ellipticine-DNA adducts in the livers of HRN mice were lower (by up to 65%) than in 262 
the livers of WT mice, demonstrating that CYP enzyme activity is important for the oxidative 263 
activation of ellipticine to metabolites generating these adducts. Whereas hepatic CYP-mediated 264 
ellipticine DNA binding was reduced in HRN mice, DNA binding in extrahepatic organs was increased 265 
(Figure 5). Up to 4.7-fold higher levels of DNA adducts were found in extra-hepatic organs of HRN 266 
mice than of WT mice (Figure 5), suggesting that these tissues have the metabolic capacity to oxidize 267 
ellipticine and, more importantly, that the same reactive species forming DNA adducts are produced in 268 
the liver, probably by both CYP-catalyzed ellipticine activation and also independently of activation by 269 
these enzymes.  270 
Figure 5. Total levels of ellipticine-DNA adducts determined and quantified by 32P-271 
postlabelling analysis of DNA isolated from organs of HRN and WT mice treated i.p. with (10 272 
mg ellipticine/kg body weight. F = fold higher and /or lower DNA adducts in HRN than WT 273 
mice. Columns, mean; bars, SD (n=3); each DNA sample was analysed twice. *P<0.05, 274 
**P<0.01, ***P<0.001.  RAL, relative adduct labelling. ND = not detected. 275 
 276 
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Experiments utilizing the ex-vivo incubations of ellipticine with hepatic microsomes of WT and 289 
HRN mice and those of these mice exposed to BaP, as well as employing inhibitors of the most 290 
important CYP enzymes catalyzing detoxification and activation of ellipticine in vitro, CYP1A and 3A, 291 
respectively, help to resolve which of these CYPs play a role in the used mouse models. As it was 292 
expected, treatment of WT and HRN mice with BaP led to a significant increase in expression of 293 
CYP1A, predominantly of CYP1A1 in liver (up to 175-fold), both at the transcriptional and translation 294 
levels [50,54]. This carcinogen increased also the expression of POR protein and its enzymatic activity 295 
in livers of these mouse models, but to a much lower extent, up to 2.9-fold. More interestingly, 296 
exposure of WT and HRN mice to BaP was also found to results in an increase in expression of another 297 
protein of the microsomal mixed-function-oxidase enzymatic system, cytochrome b5, in livers of these 298 
mice [55].  299 
Figure 6. DNA adduct formation by ellipticine activated with microsomes isolated from livers 300 
of untreated Hepatic Cytochrome P450 Reductase Null (HRN) and wild-type (WT) mice (A) 301 
and from those treated with BaP (B) as determined by thin layer chromatography (TLC) 32P-302 
postlabeling. F = fold higher DNA adducts levels in microsomes from WT mice compared to 303 
HRN mice. Columns: Mean RAL (relative adduct labeling) ± standard deviations (S.D.) 304 
shown in the figure represent total levels of DNA adducts of four determinations (duplicate 305 
analyses of two independent in vitro incubations). Values significantly different from HRN 306 
mice:*P<0.05, **P<0.01, ***P<0.001. Control = without cofactor; AA = arachidonic acid; 307 
α-NF = α-naphthoflavone; α-LA = α-lipoic acid. ND = not detected. 308 
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and mice treated with BaP led to activation of this drug to ellipticine-derived DNA adducts (Figures 2 328 
and 6), confirming a role of CYPs in ellipticine activation. Arachidonic acid, a cofactor for COX-329 
dependent oxidation [23,53,59-61], mediated formation of ellipticine-DNA adducts 1 and 2 in hepatic 330 
microsomes of all mice used, too. This suggests that COX also activate ellipticine in mouse liver 331 
[39,50]. But arachidonic acid as a cofactor of this enzyme was much less effective than a cofactor of 332 
POR and CYP, NADPH (Figure 6).  333 
Surprisingly, levels of ellipticine-derived DNA adducts formed in the ex-vivo incubations in the 334 
presence of NADPH were only 1.4-fold lower than amounts formed by hepatic microsomes from WT 335 
mice (Figure 6), even though POR expression in livers of HRN mice was two orders of magnitude 336 
lower. This finding indicates that ellipticine activation should, at least partially, be catalyzed also by 337 
enzymes, whose activities are not dependent on POR [39]. Beside peroxidases that were found to 338 
activate ellipticine [23], the CYP2S1 enzyme, which is abundantly expressed in several tissues [62-65] 339 
might be such an enzyme. Namely, it was shown that it catalyzes the oxidation of compounds having 340 
polycyclic aromatic structures similar to ellipticine without participation of POR [64,65]. Whereas a 341 
role of a COX peroxidase in hepatic microsomes of WT and HRN mice was proved in the study with 342 
these animal models (see Figure 6) [39,50], the participation of CYP2S1 in ellipticine activation awaits 343 
further examination. Therefore, the human recombinant CYP2S1 enzyme heterogously expressed in 344 
Escherichia coli was prepared in our laboratory [66] and will be utilized to investigate efficiency of 345 
this CYP in ellipticine oxidation in an additional study. 346 
At least two adducts (spots 1 and 2 in Figure 2A,B), which were identical to those generated in vivo 347 
in mice treated with ellipticine (Figure 2E,F) were formed by mouse hepatic microsomes. Furthermore, 348 
ellipticine-derived DNA adduct, spot A, was found as a minor adduct (Figure 2A), predominantly in 349 
microsomes isolated from HRN mice [39]. In incubations containing hepatic microsomes of WT and 350 
HRN mice treated with BaP, an additional adduct spot, corresponding to the 10-(deoxyguanosin-N2-351 
yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (dG-N2-BPDE) adduct that is the major 352 
product of reaction of BaP metabolite BaP-7,8-dihydrodiol-9,10-epoxide with DNA in vitro and in vivo 353 
[54,67] was also detected (Figure 2B). This finding indicates that residual BaP is present in 354 
microsomes isolated from livers of WT and HRN mice treated with BaP, and is activated by CYP1A1 355 
in combination with microsomal epoxide hydrolase to form this adduct.  356 
Ketoconazole, a selective inhibitor of CYP3A enzymes [68,69], inhibited formation of ellipticine-357 
DNA adducts in hepatic microsomes of untreated (control) WT and HRN mice, by ~60% (Figure 6A), 358 
confirming a role of CYP3A in ellipticine activation in mouse liver. However, the effect of this 359 
inhibitor was much lower in hepatic microsomes of BaP-treated WT and HRN mice, only by ~10% 360 
(Figure 6B). Hence, a contribution of CYP3A to formation ellipticine-derived DNA adducts in livers 361 
was decreased by induction of CYP1A1 with BaP. These results point additionally to CYP3A enzymes 362 
as having a role in ellipticine-DNA adduct formation in mouse livers, but their contributions to this 363 
process was decreased by induction of CYP1A with BaP. Surprisingly, an increased level of CYP1A 364 
by its induction with BaP, the enzymes that mainly detoxify ellipticine in vitro, led to an increase in 365 
amounts of ellipticine-DNA adducts formed (Figure 6), predominantly of adduct 1 [50]. Moreover, a 366 
selective inhibitor of CYP1A activities, α-naphthoflavone (α-NF) [68], decreased formation of 367 
ellipticine-DNA adducts. Both these findings prove that mouse hepatic CYP1A are required for 368 
ellipticine activation (Figure 6). Induction of CYP1A in HRN mice by BaP also resulted in an increase 369 
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in levels of ellipticine-DNA aducts, however, in hepatic microsomes of these HRN mice, α-NF caused 370 
an increase rather than a decrease in formation of ellipticine-DNA adducts (Figure 6). Therefore, here 371 
the amounts of CYP1A enzymes induced by BaP seem to increase ellipticine detoxification (see also 372 
below).  373 
Figure 7. Levels of ellipticine metabolites formed by hepatic microsomes (0.2 mg protein) of 374 
Hepatic Cytochrome P450 Reductase Null (HRN) and wild-type (WT) mice from 10 µM 375 
ellipticine and by hepatic microsomes of HRN and WT mice treated intraperitoneally (i.p.) 376 
with 5 × 125 mg of benzo[a]pyrene (BaP) per kg of body weight. Levels of ellipticine 377 
metabolites were determined by high performance liquid chromatography (HPLC) [22,49] and 378 
are averages ± standard deviations of triplicate incubations. Values significantly different from 379 
untreated mice: *P<0.05, **P<0.01, ***P<0.001  380 
 381 
 382 
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form DNA adducts in mouse liver [39,50]. These discrepancies were explained in further studies (see 405 
bellow).   406 
4.2. Utilization of Wistar rats to identify enzymes metabolizing ellipticine in vivo 407 
In order to identify CYP enzymes responsible for activation and detoxification of ellipticine in vivo 408 
further, Wistar rats were used as another animal model. Also in this animal model, when treated with 409 
ellipticine, ellipticine-derived DNA adducts were generated in DNA of several healthy organs (liver, 410 
kidney, lung, spleen, breast, heart and brain) (see Figure 2G for rat liver) [3,24,28] and in DNA of 411 
breast adenocarcinoma [3]. The levels of ellipticine-derived DNA adducts generated in breast 412 
adenocarcinoma were almost 2-fold higher than in normal healthy breast tissue. This finding indicates 413 
that CYP enzymes activating ellipticine should be expressed at higher levels in this breast 414 
adenocarcinoma such as a typical CYP expressed in breast cancer, CYP1B1 [32], than in peritumoral 415 
tissues. Indeed, such results were found by us [32] and by other authors previously [70-72].  416 
Also in rats, formation of ellipticine-DNA adduct 1 is dependent not only on levels of CYP3A, but 417 
also on those of CYP1A1. The levels of ellipticine DNA adduct 1 in analyzed organs correlated not 418 
only with expression levels of CYP3A, but also with that of CYP1A1 in these organs, which does not 419 
corresponds to situation in vitro. As outlined above, in the in-vitro systems, CYP3A is mainly 420 
responsible for formation of ellipticine-DNA adducts and CYP1A predominantly oxidizes ellipticine to 421 
its detoxification metabolites [3,4,27]. The in-vitro studies investigating the effect of cytochrome b5 on 422 
the metabolism of ellipticine explained the discrepancies between CYP enzymes oxidizing ellipticine 423 
in vitro and in vivo, and found a crucial role of this protein in contribution of individual CYP enzymes 424 
to ellipticine activation and detoxification. Moreover, increased protein expression of cytochrome b5 in 425 
liver of rats treated with ellipticine [26,42] suggests that cytochrome b5 may modulate the CYP-426 
mediated bioactivation and detoxification of ellipticine in this animal model in vivo.  427 
Cytochrome b5 is an important component of the microsomal mixed-function-oxidase system and 428 
can influence the metabolism of xenobiotics [58,67,73-78]. For more than four decades, the role of 429 
cytochrome b5 in CYP catalysis has been controversial, and based entirely on in vitro data, which 430 
showed that cytochrome b5 could inhibit or stimulate CYP activity dependent on a number of variables 431 
including CYP isoenzyme, substrate and cytochrome b5 concentration [73-78]. In order to investigate 432 
the role of cytochrome b5 in ellipticine metabolism we conducted some in vitro experiments using 433 
human liver microsomes, hepatic microsomes from control and ellipticine-pretreated rats and 434 
reconstituted systems with CYP1A1, CYP1A2, CYP3A4, POR, and cytochrome b5 in different ratios 435 
[25,26,30,40,42,80]. We have found that cytochrome b5 alters the ratio of ellipticine metabolites 436 
generated by CYP1A1, 1A2, and 3A4. Whereas the amounts of the detoxication ellipticine metabolites 437 
(7-hydroxy- and 9-hydroxyellipticine) are either decreased (CYP1A1/2) or not changed (CYP3A4) 438 
with cytochrome b5 added to the reconstituted system, the amounts of the activation metabolites, 12-439 
hydroxy- and 13-hydroxyellipticine, increased considerably. The change in the amounts of metabolites 440 
found in these studies resulted in higher ellipticine-DNA adduct levels [25,26,30]. In these enzymatic 441 
systems the ratios of the various partners of CYP are artificially generated, therefore a more 442 
physiological model to identify human enzymes responsible for ellipticine activation was used, namely, 443 
human hepatic microsomes [22,30]. These microsomal fractions contain a mixture of human CYPs, 444 
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POR, cytochrome b5 and its reductase (NADH:cytochrome b5 reductase). Thus, they comprise the 445 
essential components of the enzymatic system metabolizing drugs, mimicking well a situation in 446 
human liver, where a majority of drug metabolism occurs [67,79]. Human hepatic microsomes oxidize 447 
ellipticine mainly to 13-hydroxy- and 12-hydroxyellipticine, whereas 7-hydroxy-, 9-hydroxyellipticine 448 
and ellipticine N2-oxide are generated at more than 10-fold lover amounts (see Table 2 in [30]). Similar 449 
results were found in hepatic microsomes of rats [49]. As a consequence, high levels of both major 450 
ellipticine-DNA adducts are formed when DNA is added to the microsomal incubations. The amounts 451 
formed correlated with the activity of the major CYPs found previously to form the metabolites 452 
generating these DNA adducts (see above) [22,30]. 453 
All these results explained the reasons why the CYP1A enzymes are more important in ellipticine 454 
activation in vivo; their activity is modulated by cytochrome b5. These results also demonstrated that 455 
not only the expression levels of CYP1A and 3A in several organisms including human, but also the 456 
amounts of expressed cytochrome b5 dictate the oxidative activation and detoxification of ellipticine in 457 
vivo. Moreover, because ellipticine itself is capable of inducing expression of CYP1A (predominantly 458 
CYP1A1), POR, and cytochrome b5 [42,80], it increases its own metabolism leading predominantly to 459 
activation of this drug to reactive species forming DNA adducts [25,26], thereby modulating its own 460 
pharmacological potential.  461 
The ellipticine-derived DNA adducts formed by enzymatic activation of ellipticine in vitro and in 462 
vivo were also found in tumor cells, in which CYP enzymes are expressed. The adducts were found in 463 
human breast adenocarcinoma MCF-7 cells [32], neuroblastoma IMR-32, UKF-NB-3, and UKF-NB-4 464 
cells [34,35], glioblastoma U87MG cells [37], and BHT-101, B-CPAP and 8505-C thyroid cancer cells 465 
[36] exposed to ellipticine. Cytotoxicity of ellipticine corresponds to amounts of ellipticine-DNA 466 
adducts formed in the tested cancer cells and depends on expression levels of CYP enzymes 467 
metabolizing ellipticine (CYP1A1, 1B1, and 3A4) and/or cytochrome b5 in these cells [27,32,34-37]. 468 
The high expression levels of cytochrome b5 together with those of CYP1A1 and 3A4 dictate the DNA 469 
adduct formation by and cytotoxicity of ellipticine also in most of these cancer cells, predominantly in 470 
neuroblastoma UKF-NB-4, glioblastoma U87MG and thyroid cancer cell lines [11,27,32,34-36]. These 471 
findings again demonstrate a role not only of the expression of CYPs, but also of cytochrome b5, 472 
because it dictates the pharmacological effects of ellipticine. 473 
Concerning formation of ellipticine-derived DNA adducts in the healthy organs of experimental 474 
models in vivo [24,28,39], it should be emphasized that expression levels of CYP enzymes activating 475 
ellipticine in these tissues might determine also genotoxic side effects of ellipticine in these tissues. 476 
Indeed, several studies have found a positive correlation between DNA adduct levels of carcinogens or 477 
genotoxic agents, their persistence and their mutagenicity in the target organ and/or tumor formation 478 
[81-85]. Therefore, to better understand the role of ellipticine-DNA adducts in such genotoxic side 479 
effects of ellipticine in the cancer treatment, we have analyzed the dose dependence and the persistence 480 
of ellipticine-DNA adducts in non-target tissues (liver, lung, kidney, spleen, heart, and brain) of rats, 481 
the animal model mimicking the bioactivation of ellipticine in human, treated with ellipticine [24]. 482 
Only very low levels of the adducts and only in some of tissues analyzed in such a study were retained 483 
in DNA of these non-target tissues. In addition, not all of the ellipticine-DNA adducts persist in the 484 
tissues analyzed in the study (only adducts 1, 2, 4, and 5) [24]. This finding demonstrates that healthy 485 
tissues of rats treated with ellipticine posses effective repairing systems to remove certain lesions and 486 
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suggests a relatively low impact of the genotoxic side effects of ellipticine during the cancer treatment 487 
in human. 488 
5. Conclusions 489 
The data summarized in this review demonstrate that a DNA-damaging anticancer alkaloid 490 
ellipticine might be considered as a prodrug, whose major mechanism of action is mediated by the 491 
enzyme-catalyzed activation leading to formation of covalent DNA adducts in target tissues. These 492 
ellipticine-DNA adducts are formed in both healthy and tumor tissues, but they do not persist in 493 
healthy tissues. The data show that cytotoxic effects of ellipticine in tumor tissues (cells) are dictated 494 
by (i) levels of CYP expression (and/or peroxidase expression), (ii) levels of cytochrome b5 expression, 495 
and (iii) its own potency to induce CYP1A1, CYP3A and cytochrome b5 in tumor tissues (cells). The 496 
results found also demonstrate that animal models, where levels of biotransformation enzymes are 497 
regulated both by their knockout or induction are appropriate tools to identify enzymes responsible for 498 
ellipticine metabolic activation and detoxification. They also demonstrate that extrapolation from in 499 
vitro data to situation in vivo is not always possible, confirming the need for these animal models.  500 
Even though the role of cytochrome b5 in modulation of ellipticine metabolism in vitro was clearly 501 
proved, its effect in vivo is still quite enigmatic. Two mouse lines such as a line that has been generated 502 
with a conditional hepatic deletion of cytochrome b5 (HBN, Hepatic cytochrome b5 Null) [86] and a 503 
double conditional mutant, HBRN (Hepatic cytochrome b5 /P450 Reductase Null), in which both 504 
enzymes are deleted specifically in the liver [87], recently developed in the laboratory of Wolf and 505 
coworkers [86,87] can provide a study to resolve the role of cytochrome b5 in CYP-mediated 506 
metabolism of ellipticine in vivo.  507 
The results summarized in this review form the basis to further predict the susceptibility of human 508 
cancers to ellipticine   and suggest this alkaloid for treatment in combination with CYP gene transfer 509 
(CYP-gene-directed enzyme-prodrug therapy) [88,89], which has the potential to provide efficient 510 
activation of ellipticine in target tumor tissue, thereby increasing the anticancer potential of this 511 
prodrug. Furthermore, two of the ellipticine metabolites formed by oxidation with CYPs in 512 
combination with  cytochrome b5, 13-hydroxy- and 12-hydroxyellipticine, are reactive enough to 513 
decompose spontaneously to the carbenium ions forming  DNA adducts that are predominantly 514 
responsible for killing cancer cells. Both these ellipticine metabolites are, therefore, excellent 515 
candidates for tumor cell-specific targeting to these cancers that include the use of systemic delivery of 516 
these metabolites. Therefore, we suggest these two ellipticine derivatives for potential clinical usage. 517 
Further, preparation of appropriate derivatives including their encapsulated forms in nanocarriers that 518 
would deliver them to cancer cells is one of the major challenges in research of our laboratory to 519 
prepare suitable ellipticine derivatives for clinical usage. 520 
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